-+ 0.00%
-+ 0.00%
-+ 0.00%

SCYNEXIS Says First Participants Dosed In Phase 1 SAD And MAD Trial Evaluating IV Of Second-Gen Triterpenoid Antifungal Therapy, SCY-247; Trial Results Expected In 2026

Benzinga·02/26/2026 13:26:20
Listen to the news

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the first participants have been dosed in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial evaluating the intravenous formulation (IV) of its second-generation triterpenoid antifungal therapy, SCY-247, which is being developed as a treatment for invasive candidiasis (IC) and as a prophylaxis therapy for invasive fungal disease. Results from this trial are expected in 2026.